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OBJECTIVES In the present study, we analyzed the clinical outcome of patients with multivessel coronary
artery disease in whom at least one vessel was treated by percutaneous coronary intervention
(PCI) and at least one other vessel was deferred on the basis of fractional flow reserve (FFR)
measurements during the same session.
BACKGROUND Myocardial FFR is an established tool for assessing the severity of epicardial stenoses. It has
been shown that it is safe to defer an intervention in single vessel disease patients when FFR
0.75.
METHODS One hundred two patients (66  10 years) with multivessel coronary artery disease were
included in the study. In all patients, PCI of at least two vessels was contemplated. Yet in all
of them at least one vessel was treated by PCI, whereas at least one other vessel was deferred
based on an FFR 0.75. Major adverse cardiac events (MACE) were recorded during an
average follow-up of 29  18 months.
RESULTS In 102 patients, 113 coronary arteries underwent PCI. In these arteries FFR was 0.57  0.13
and mean diameter stenosis was 68  14%. One hundred twenty-seven coronary arteries had
an FFR 0.75 and PCI was deferred. In these arteries FFR was 0.86  0.06 and mean
diameter stenosis was 47  12%. No death occurred during the follow-up. A MACE
occurred in 9% and 13% of patients after 12 and 36 months, respectively. These MACE were
related to 22 (9.2%) arteries. Among them, 8 (6.3%) MACE were related to one of the
initially deferred vessels, whereas 14 (12.3%) MACE were related to one of the initially
treated coronary artery.
CONCLUSIONS In patients with multivessel disease, PCI of hemodynamically non-significant stenoses can be
safely deferred, even if initially planned on the basis of the angiogram. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.0412005;46:438–42) © 2005 by the American College of Cardiology Foundation
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Cnducible myocardial ischemia at non-invasive stress testing
s a paramount prognostic factor (1,2) and its documenta-
ion remains essential prior to invasive evaluation. Nowa-
ays, however, the majority of percutaneous coronary inter-
entions (PCIs) are performed without prior non-invasive
tress testing (3). In addition, in patients with multivessel
oronary disease, the diagnostic accuracy of perfusion scans
s poor in assessing which stenosis is hemodynamically
ignificant (4). Fractional flow reserve (FFR) is an invasive
ndex of the hemodynamic significance of stenosis severity
ith a diagnostic accuracy similar to myocardial perfusion
can but a better spatial resolution. It is derived from the
atio between coronary and aortic pressure measurements
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ecipient of a British Heart Foundation Advanced Training Scholarship and was also
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ccepted April 13, 2005.uring maximal hyperemia. As this index is easy to measure
nd available in a few minutes in the catheterization
aboratory, it can be used as a surrogate for non-invasive
esting (5). The usefulness of FFR in patients referred for
CI with intermediate stenoses was demonstrated in single
essel diseased patients (6). In the present study we analyzed
he clinical outcome of patients with multivessel coronary
rtery disease in whom at least one vessel was treated by PCI
nd at least one other vessel was deferred on the basis of
FR measurements during the same session.
ETHODS
tudy patients. Patients with multivessel coronary artery
isease at angiography were included in the study if at least
ne artery was treated by PCI and, during the same
rocedure, at least one stenosis was deferred from PCI on
he basis of an FFR 0.75. The study was performed in the
ardiovascular Center Aalst, Belgium, and in the Catharina
ospital in Eindhoven, the Netherlands, from June 1994 to
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August 2, 2005:438–42 FFR and Multivessel Diseaseay 2002. Fractional flow reserve and quantitative coronary
rteriography were obtained in all patients. Moreover, all
atients were informed beforehand that the therapeutic
trategy would be guided by pressure measurements.
oronary pressure measurement and calculation of FFR.
he FFR was measured in all stenoses in which PCI was
ontemplated except stenoses with a Thrombolysis In Myo-
ardial Infarction (TIMI) flow grade 3, and stenoses of
hich the significance had been demonstrated at perfusion
cintigraphy. Intracoronary pressure measurements were
erformed with a 0.014-inch pressure guidewire (Radi
edical System, Uppsala, Sweden) introduced through a
-F guiding catheter. The FFR was calculated from the
atio of mean hyperemic distal coronary pressure measured
y the pressure-wire and the mean aortic pressure obtained
y the guiding catheter (7,8). All patients received aspirin
nd either clopidogrel or ticlopidine for at least two months.
uantitative coronary arteriography. Reference diameter
RD), minimum luminal diameter (MLD), and percent
iameter stenosis (DS) were assessed in two views during
he PCI procedure.
ollow-up and clinical events. All patients were evaluated
t the outpatient clinic or by mail. Major adverse cardiac
vents (MACE) were defined as death, myocardial infarc-
ion (MI), and any repeat (target or non-target) vessel
evascularization (TVR). Myocardial infarction was defined
s the occurrence of new Q waves or a rise in creatinine
hosphokinase of more than twice the upper limit (6). A
epeat angiogram was not performed unless clinically indi-
ated. The culprit artery vessel responsible for the recur-
ence of symptoms was defined by the operator’s judgment,
ased on the correlation of electrocardiographic changes,
chocardiographic data (if available), and the diagnostic
ngiogram.
tatistics. Because of the design of the study, the unit of
nalysis became the coronary artery lesion rather than the
atient. Therefore, potential correlations within patients
ould have been ignored. Continuous variables were ex-
ressed as mean  standard deviation and discrete variables
s counts and percentage. The chi-square test and the Fisher
xact t test were used for categorical variables, and the
Abbreviations and Acronyms
ACS  acute coronary syndrome
%DS  percent diameter stenosis
FFR  fractional flow reserve
LAD  left anterior descending artery
LCx  left circumflex artery
MI  myocardial infarction
MLD minimal lumen diameter
RCA  right coronary artery
RD  reference diameter
TVR  target vessel revascularizationtudent t test was used for continuous variables. Clinical,
M
Rngiographic variables, and FFR values were compared
etween the deferred- and the treated-vessels groups. Sur-
ival curves were constructed according to the Kaplan and
eier method and compared by the log-rank test. A p value
0.05 was considered statistically non-significant.
ESULTS
opulation. One hundred two patients (240 arteries, mean
ge 66  10 years, 71% men) were included. Eighteen
ercent of patients had diabetes, 34% hypertension, 29%
ere current smokers, 50% had dyslipidemia, and 43% had
positive familial history for ischemic heart disease. Most
atients had stable angina (76%), and the remainder pre-
ented an acute coronary syndrome (ACS) (21 with unstable
ngina and 3 with non–ST-segment elevation MI). Angio-
raphic and hemodynamic data of the treated and deferred
rteries are shown in Table 1.
ngiographic and hemodynamic results. Thirty-five pa-
ients (34%) had three-vessel disease and 66 patients (66%)
ad two-vessel disease. The PCI procedure was performed
n 113 coronary arteries: 1 artery was treated in 91 patients
nd 2 arteries in 11 patients. In patients admitted for an
CS, the “culprit” lesion was treated in all cases. Use of PCI
as deferred based on an FFR 0.75 in 127 coronary
rteries: in one artery in 77 patients and in two arteries in 25
atients. The individual values of FFR and of %DS for the
reated and the deferred arteries are shown in Figure 1. By
esign, FFR was 0.75 in deferred arteries. In this group
he mean value of FFR was 0.86  0.06 (range 0.75 to 1.0).
he FFR value in the treated arteries was 0.57  0.13
range 0.29 to 0.74). DS of the treated arteries (68  14%,
ange 30% to 100%) was significantly higher than in the
eferred arteries (47  12%, range 15% to 74%, p  0.001)
ut a large overlap of the values was observed.
Among the 21 patients presenting with an ACS, a TIMI
ow grade 3 was present in 6 culprit arteries. The FFR
able 1. Angiographic and Hemodynamic Data of Treated and
eferred Lesions
Treated Lesions
(n  113)
Deferred Lesions
(n  127) p Value
oronary lesions
LAD 42 (37%) 53 (42%) NS
LCx 39 (35%) 40 (32%) NS
RCA 32 (28%) 28 (22%) NS
LM 0 6 (4%) NS
CA (mean  SD)
%DS 68  14 47  12 0.0001
MLD (mm) 0.90  0.4 1.5  0.5 0.0001
RD (mm) 2.80  0.82 2.83  0.79 NS
emodynamic variables
(mean  SD)
FFR 0.57  0.13 0.86  0.06 0.0001
DS  percent diameter stenosis; FFR  fractional flow reserve values; LAD  left
nterior descending artery; LCx  left circumflex artery; LM  left main artery;LD  minimal lumen diameter; QCA  quantitative coronary arteriography;
CA  right coronary artery; RD  reference diameter.
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FFR and Multivessel Disease August 2, 2005:438–42as measured in 15 culprit arteries in which flow was
ormal (0.53  0.13, range 0.29 to 0.7) and in 28 non
ulprit arteries (0.85  0.06, range 0.76 to 0.99).
ollow-up. Mean follow-up was 29  18 months. No
eaths occurred. A MACE occurred in 9 (9%) and in 13
13%) patients after 12 and 36 months, respectively. These
ACE were related to 22 (9.2%) vessels. Among them, 8
6.3%) MACE were related to the initially deferred stenosis,
igure 1. Individual values of fractional flow reserve (FFR) and individual
he black dots indicate the stenoses responsible for a major adverse cardia
ine indicates the cut-off value of FFR (0.75).
able 2. Characteristics of Patients in Whom a MACE Was Ob
Gender/Age Indication Vessel FFR
ACEs related to the deferred arteries
M/74 Stable RCA 0.88
M/41 Stable RCA 0.82
M/75 Stable RCA 0.87
M/82 Stable RCA 0.86
M/62 Stable LAD 0.87
M/69 Stable LCx 0.91
M/54 ACS LAD 0.76
F/56 ACS LAD 0.9
ACEs related to the treated arteries
F/79 Stable LCx 0.46
M/82 Stable LAD 0.57
M/70 Stable RCA 0.33
M/41 Stable LAD 0.55
M/70 Stable LCx NM
M/41 Stable LCx NM
F/58 Stable LCx 0.73
F/80 ACS RCA NM
M/55 ACS LAD 0.65
F/67 Stable RCA 0.63
M/67 Stable RCA 0.72
F/57 Stable LAD 0.51
F/56 ACS LCx NM
F/44 ACS LCx 0.29
haded area shows deferred-vessel group; unshaded area shows treated vessels.
ACS  acute coronary syndrome; MACE  major adverse cardiac events; MI  myoca
bbreviations as in Table 1.hereas 14 (12.3%) MACE were due to the initially treated
rtery. Only one MACE was related to a stenosis with an
FR between 0.75 and 0.80.
At their last follow-up, 47% of patients received statins,
5% beta-blockers, and 25% angiotensin-converting enzyme
nhibitors. Table 2 displays details of the MACE. The occur-
ence of events as a function of time is shown in Figure 2.
here was no difference between treated and deferred
s of the percent diameter stenosis (%DS) in treated and deferred arteries.
ts at follow-up. Mean values are shown in both groups (bar). The dotted
d During Follow-Up
%DS
MLD
(mm) Type of MACE
Follow-Up
(Months)
30 1.77 TVR 1
45 1.21 TVR 4
38 1.59 TVR 6
46 1.71 TVR 8
58 1.59 MI  TVR 9
54 1.02 TVR 13
62 0.64 TVR 19
50 1.5 TVR 26
68 0.57 TVR 2
75 0.8 TVR 3
79 0.6 MI  TVR 3
67 0.67 TVR 4
53 1.5 TVR 4
51 1.36 TVR 4
50 1.0 TVR 6
95 0.25 TVR 6
57 1.38 TVR 8
76 1.08 TVR 17
63 1.0 TVR 22
46 0.82 TVR 25
91 0.25 TVR 26
61 0.8 MI  TVR 27valueserverdial infarction; NM  not measured; TVR  target vessel revascularization; other
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August 2, 2005:438–42 FFR and Multivessel Diseaserteries (log rank test; p  0.64). No differences existed in
he MACE rate between stable and unstable patients (19%
s. 28%, p  0.56).
ISCUSSION
he results of the present extend the usefulness of FFR in
linical decision making to patients with multivessel disease.
he strategy of not performing PCI on stenoses associated
ith an FFR 0.75 while treating only stenoses that are
emodynamically significant appears safe. In these patients,
rteries with an FFR 0.75 and that were initially left
ntreated required PCI in 5.9 % of cases after one year and
n 6.3% after three years. No deaths occurred and only one
yocardial infarction occurred in relation to the initially
eferred artery. These numbers are similar to the clinical
vent rates reported after 12 months in the “real-world”
egistry RESEARCH of sirolimus-eluting stents (SES) for
atients with multivessel coronary disease. Among the 99
atients with multivessel disease and left anterior descend-
ng coronary artery (LAD) involvement, the survival free of
I and repeat revascularization was 85.6% after SES
mplantation after one year (9). Taken together these data
uggest that, in patients with two- or three-vessel disease, it
s at least as appropriate to defer a hemodynamically
on-significant stenosis than to perform PCI.
FR in patients with one-vessel disease and in left main
isease. Studies have shown that in patients, scheduled for
ne-vessel PCI, it was safe to defer the intervention when
he FFR was 0.75. A multicentric randomized trial
ncluded a total of 325 patients who were scheduled for
ingle-vessel PCI but without any non-invasive stress test-
ng (6). The FFR values 0.75 were measured in 181
atients. Among these patients, event-free survival after one
ear was 92% when PCI was deferred and 89% when PCI
as actually performed. After two years the corresponding
alues were 89% and 83%, respectively. A large overlap
xisted in the values of %DS observed in vessels with an
igure 2. Cumulative major adverse cardiac events (combined end points
f death, myocardial infarction, and target vessel revascularization) rate
urves (Kaplan-Meier) for treated, deferred vessels, and for the entire
atient population.FR 0.75 and in those with an FFR 0.75, indicating nhat angiography is not able to distinguish hemodynamically
ignificant from non-significant stenoses. In addition, the
ercentage of patients free from angina after two years was
imilar in the two groups. These results indicated that there
s no benefit in treating the stenoses with an FFR 0.75.
wo studies have extended these results to moderate left
ain disease (10,11). Both concluded that when FFR is
0.75, no revascularization of the left main stenosis should
e proposed. Both studies, however, are based on small
umbers of “deferred” patients, and the values of FFR
hould be applied with caution to individual patients. In
ddition, isolated left main stenoses are rare, and the value
f FFR measured in a left main stenosis is often influenced
y the presence of other stenoses in the LAD or in the left
ircumflex artery (LCx).
FR for clinical decisions in multivessel disease. In
atients with multivessel disease the spatial resolution of
on-invasive testing is poor. Only a minority of patients
ith severe three-vessel disease exhibit a “multivessel pat-
ern” at gated single-photon emission computed tomogra-
hy myocardial perfusion imaging (5). In contrast, FFR
erformed in all three vessels provides the operator in the
atheterization laboratory with precise functional informa-
ion that cannot be obtained from non-invasive testing.
hamuleau et al. (12,13) analyzed the clinical follow-up of
atients with multivessel disease in whom the myocardial
PECT perfusion imaging showed no perfusion defect in a
egion supplied by an angiographically intermediate stenosis
nd in which FFR had been measured. The decision to
erform PCI was based on the results of the perfusion
cintigram. The investigators showed that the event rate was
ignificantly higher (relative risk of 3.1) when, on the basis
f a normal perfusion scan, no revascularization was per-
ormed despite an FFR 0.75. In other words, FFR is
uperior in detecting a hemodynamically significant stenosis
n patients with multivessel disease at angiography.
In addition, Chamuleau’s data indicate that when FFR is
0.75, PCI is warranted even though the perfusion scan is
ormal in the region supplied by the PCI artery. Botman et
l. (14) recently reported on a “tailored approach” based on
FR measurements in patients with multivessel disease.
atients were treated by coronary artery bypass grafting (n
87) when the FFR is 0.75 in all three arteries or in two
rteries including the proximal LAD. When only one or
wo stenoses (not including the proximal LAD) were
hysiologically significant, PCI (bare metal stent implanta-
ion) of these stenoses was performed (n  63). After two
ears, there was no difference in death and MIs. More
mportantly, and in contrast to previous studies comparing
urgery and PCI in patients with multivessel disease, the
eed for repeat revascularization, along with angina status,
as similar in both groups. This “tailored approach” yielded
imilar results as the surgical group of the ARTS I study
15). In the present study, the retrospective character of the
nalysis might contribute to explain the particularly low
umber of events for patients with multivessel disease.
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FFR and Multivessel Disease August 2, 2005:438–42ONCLUSIONS
n patients with multivessel disease at angiography, FFR
llows distinction between functionally significant and non-
ignificant stenoses. The PCI of the latter can be safely
eferred, even when initially planned on the basis of the
ngiogram. In more general terms, these findings illustrate
he difference between anatomical and functional multives-
el disease, the therapeutic implications of this difference,
nd the safety and effectiveness of treatment of multi-vessel
isease based on functional assessment.
eprint requests and correspondence: Dr. Bernard De Bruyne,
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